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Abstract The hypoxia-inducible factor is the key protein
responsible for the cellular adaptation to low oxygen
tension. This transcription factor becomes activated as a
result of a drop in the partial pressure of oxygen, to hypoxic
levels below 5% oxygen, and targets a panel of genes
involved in maintenance of oxygen homeostasis. Hypoxia
is a common characteristic of the microenvironment of
solid tumors and, through activation of the hypoxia-
inducible factor, is at the center of the growth dynamics
of tumor cells. Not only does the microenvironment impact
on the hypoxia-inducible factor but this factor impacts on
microenvironmental features, such as pH, nutrient avail-
ability, metabolism and the extracellular matrix. In this
review we discuss the influence the tumor environment has
on the hypoxia-inducible factor and outline the role of this
factor as a modulator of the microenvironment and as a
powerful actor in tumor remodeling. From a fundamental
research point of view the hypoxia-inducible factor is at the
center of a signaling pathway that must be deciphered to
fully understand the dynamics of the tumor microenviron-
ment. From a translational and pharmacological research
point of view the hypoxia-inducible factor and its induced
downstream gene products may provide information on
patient prognosis and offer promising targets that open
perspectives for novel “anti-microenvironment” directed
therapies.
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Introduction
A tumor is not just a mass of individual cancer cells
multiplied infinitely but is constituted of cancer stem cells,
mature cancer cells, metastatic cancers cells, stromal cells,
endothelial cells, macrophages…all embedded in an extra-
cellular matrix (ECM). These cells must be considered
within the context of the tumor matrix, in which they
communicate with each other and interact strongly with
their local microenvironment. To obtain a better understand-
ingofthemechanismsoftumorigenicity,tumordevelopment
and metastasis an overview of the whole system integrating
the characteristics that are fundamental for cell growth
dynamics is essential. The tumor ecosystem can be seen as
an assembly of constraints put on cancer cells to which they
respond and adapt. The hypoxia-inducible factor (HIF) acts
as a key feature in microenvironmental adaptation of tumor
cells. We will describe the regulation of the expression and
activity of HIF in focusing on specific environmental
conditions including oxygen and nutrient availability as well
as the pH and the extracellular matrix. We will examine how
these constraints influence directly or indirectly the HIF
signaling pathway, and in turn how the HIF downstream
effectors can remodel the microenvironment.
Microenvironmental Oxygen Determines HIF-mediated
Gene Profiling
Oxygen Distribution in Tumors
Through evolution, Mother Nature provided oxygen as a
major resource for life. A cancer cell in close vicinity to a
blood vessel is able to use the plentiful supply of oxygen
carried by the blood to obtain energy through oxidative
phosphorylation for rapid growth. Nonetheless, cancer cell
oxygenation is limited by three convergent mechanisms: (1)
As a tumor mass expands, cancer cells develop distant from
blood vessels. The characteristic diffusion distance of
oxygen results from the conjunction of the passive physical
diffusion and active cellular oxygen consumption. Since
this diffusion distance within tumor tissue is approximately
70 μm cancer cells proliferating at the periphery of blood
vessels dispose of only a low oxygen availability [1, 2]. (2)
Moreover, blood vessels in solid tumors are known to be
highly disorganized and chaotic. This loss of coherent
structural organization diminishes the oxygen profile of the
tumor. To characterize the vascular network in tumors an
original and very informative mathematical tool: the fractal
character of the vascular system has been described [3, 4].
Histological studies have shown that the fractal dimension
of blood vessels correlates with the nature of the tumor
tissue. This dimension is higher in tumors than in non-
malignant tissues, which reveals that the vessels present
more irregularity and less homogeneity. Consequently
perfusion and irrigation in tumors is often not optimal. (3)
Finally the hematological status of cancer patients is
frequently altered, either by the disease itself or by
chemotherapy related toxicity. Hence these parameters
converge to give inadequate irrigation of the tumor and
thus low nutrient and oxygen availability. For example the
median partial pressure of oxygen (pO2) in the normal
cervix is 42 mmHg compared to only 10 mmHg in
squamous carcinomas [1, 2].
A tumor can be considered as a mosaic of blood vessels
from which oxygen will diffuse into the tumor matrix,
creating a myriad of gradients of oxygen concentrations
within a hypoxic range. Clinical studies associate the
hypoxic status of a tumor with bad prognosis and resistance
to chemo- and radio-treatment [5]. Chemo-resistance can be
explained partly by an inefficient diffusion of drugs to
poorly irrigated areas due to an increase in internal fluid
pressure. Furthermore, hypoxic radio-resistance is
explained by the fact that radiotherapy uses oxygen to
generate cytotoxic free radicals but also by active anti-
apoptotic cellular mechanisms induced by hypoxia [6].
Impact of Environmental pO2 on HIF Activity:
Oxygen-Sensing
Hypoxia is a condition encountered in both physiological
(embryonic development) and pathophysiological (ischemia
diseases, diabetes, atherosclerosis, Alzheimer’s disease,
chronic obstructive pulmonary disease, inflammatory dis-
orders, pre-eclampsia, psoriasis and cancer) situations.
Cells exposed to a hypoxic stress must rapidly adapt,
otherwise an imbalance in their energy supply/consumption
ratio ensues. Hypoxia activates a global signaling network
centered on the key element, the hypoxia-inducible factor
(HIF) [5, 7, 8]. Thus low oxygen tension is the prototypic
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panel of microenvironmental adaptation genes that contrib-
ute to rapid cell survival [5, 9, 10]. In addition to survival,
the HIF signaling pathway confers on cancer cells an
arsenal that allows them to become more aggressive. So,
how is the transcriptional machinery activated in response
to variations in the pO2? HIF is a heterodimer composed of
an O2 regulated alpha subunit and a constitutively
expressed beta subunit (Fig. 1). Several HIF alpha and beta
isoforms have been described in mammals, where HIF-1α,
HIF-2α and HIF-1β are the best characterized to date.
The basic helix-loop-helix (bHLH) domain in the N-
terminal part of HIFα confers specific DNA recognition.
DNA regions called hypoxia-response elements (HRE) are
sequences characteristic of HIF downstream target genes. In
hypoxia the heterodimer transactivates target HRE contain-
ing genes (1 to 2% of the genome is probably modulated by
hypoxia). HIFα functional recruitment of RNA polymerase
is driven by its transcriptional activation domains (TAD)
where HIF-1α and HIF-2α share the distinctive feature of
bearing two TADs: N-terminal (N-TAD) and C-terminal
(C-TAD) (Fig. 1). The half-life of the HIFα protein in the
presence of 21% oxygen is less than 5 min, and increases to
60 min as the O2 concentration decreases to 1%. On
reoxygenation, the HIFα protein is degraded after only a
few minutes. As the O2 concentration does not impact on
the HIFα mRNA level, HIF is regulated exclusively
posttranslationally by the pO2.
The mechanisms by which cells sense and respond,
through HIF, to environmental oxygen was revealed in the
early 2000s. Dioxygenases catalyze protein hydroxylation,
a reaction requiring ambient O2, that leads to the formation
of an −OH group on HIFα proteins. Oxygen-sensor
dioxygenases target the HIFα subunit and are thus termed
HIF-hydroxylases. Two types of HIF-hydroxylases have
been characterized to date: (1) HIF-prolyl hydroxylases;
though preferably referred to as prolyl hydroxylase domain
(PHD) proteins since substrates other than HIF have been
and are probably still to be identified, and (2) HIF-
asparaginyl hydroxylase also called factor inhibiting HIF-1
(FIH) [11].
Three major PHD isoforms have been described and
catalyze the hydroxylation of two prolyl residues of the
HIFα subunit, an action that strictly depends of the pO2
[12–14]. These two residues are located in the oxygen-
dependent degradation (ODD) domain of HIFα and when
hydroxylated this domain shows a strong affinity for the
von Hippel-Lindau (VHL) protein, a component of a E3
ubiquitin ligase complex. The consequence is poly-ubiq-
uitination and targeting of HIFα for degradation by the
proteasome (Fig. 2). Thus an increase in HIFα protein levels
in hypoxia is due to the inhibition of this oxygen-dependent
degradation process.
The second oxygen sensor FIH catalyzes asparaginyl
hydroxylation in the C-terminal TAD of HIFα when in the
presence of oxygen [11] (Fig. 2). This results in a change in
the local hydrophilic/hydrophobic balance of the protein
and impairs the interaction between the hydroxylated
C-TAD and one of its essential coactivators: p300/CREB
binding protein (CBP) [15, 16]. This abolishes the C-TAD
activity, however, inhibition is progressively alleviated as
the pO2 decreases towards anoxia.
Thus, HIF hydroxylation is a double locking system. In
normoxia HIF is degraded by highly active PHDs but if a
Fig. 1 Schematic of the structure of the three HIFα and the two HIFβ
isoforms. NLS, nuclear localization signal; bHLH, basic helix-loop
helix-domain; PAS, per arnt sim domain subdivided into PAS A and
PAS B; ODD, oxygen-dependent degradation domain; TAD, trans-
activation domain. HIF-1α and HIF-2α have two distinct TAD, in the
C- (C-TAD) and N- (N-TAD) terminal domains. The PAS and bHLH
domains are dedicated to dimerization and recognition of target DNA
sequences
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inactivated by FIH. When the oxygen tension decreases,
HIF is stabilized and becomes fully active via its two TADs
(Fig. 2).
Other forms of posttranslational modification of HIFα
including phosphorylation, SUMOylation, S-nitrosylation
and acetylation (the mechanism of the latter remains
controversial, reviewed in [17]), have been reported to
influence stability and activity [18]. Such modifications
may also contribute substantially to the hypoxic response of
cells depending on the environmental conditions.
HIF-Induced Gene Profile Selectivity
Selective modulation of the spectrum of genes induced by
HIF can occur in two ways. First, HIF-1α and HIF-2α can
differentially transactivate a series of genes. For example
adrenomedullin is a HIF-2 only gene in mouse stem cells,
carbonic anhydrase IX (ca9) is a HIF-1 targeted gene in
human HeLa cells, whereas phd3 is regulated by both HIF-
1 and HIF-2 in human cells [19, 20]. Relative HIF-1 and
HIF-2 activities differ depending on the cell type. Second,
through the bifunctional TAD activity of HIF-1α [20]
(Fig. 3a). FIH specifically hydroxylates the C-TAD, and
does not touch the N-TAD. So experimentally, FIH inhibits
only a subset of HIF-1-target genes. Knowing this we put
forward a model that divides the HIF-1 spectrum of genes
into two categories: one that is C-TAD sensitive and the
other N-TAD only sensitive. FIH would inhibit the C-TAD
spectrum and as a result pilot the shift between these two
categories of HIF-1 target genes. This double TAD
regulation model can be easily transposed to HIF-2α, since
this isoform is regulated in a highly homologous mode.
To fully understand the impact of this model, these data
must be considered in the context of an oxygen gradient
within a tissue. How do oxygen-sensors drive HIF activity
in the physiological context? Studies into the enzyme
activity showed that PHD and FIH have very different
requirements in terms of the oxygen concentration. In vitro,
the Km of PHD for O2 is three times greater than that of
FIH [21]. This corresponds respectively to oxygen concen-
trations of approximately 24% and 8% (compared to 2% for
collagen prolyl hydroxylases which are consequently
insensitive to hypoxia). This means that PHD should be
inactivated in milder (theoretically 3 times more oxygen)
hypoxia compared to FIH. However, experimentally, in
cellulo, FIH activity has been reported at 0.2% oxygen
whilst HIF-1α is maximally stabilized by complete inacti-
vation of PHD [22]. Thereby there should be areas of mild
hypoxia in the tumor where HIFα is stabilized by the
inactivation of PHD but still partially inhibited by FIH-
dependent hydroxylation of its C-TAD (Fig. 3b). In such
areas the N-TAD repertoire of HIF-dependent genes should
be induced. Further, under severe hypoxia, FIH should also
be inactivated, thus releasing the C-TAD sensitive reper-
toire. Thus this model provides a link between the induction
of a certain gene at a certain localization and the oxygen-
dependent activity of the oxygen sensor FIH (Fig. 3b).
Fig. 2 Proline hydroxylation drives HIFα stability and asparagine
hydroxylation drives HIF activity. Left panel: Under normoxic
conditions, the interaction between two hydroxy-prolyls (Pro 402
and 564 for human HIF-1α on the schematic) and the VHL protein
leads to the degradation of HIFα by the proteasome. Under hypoxic
conditions, because of the lack of the oxygen substrate, the HIF-prolyl
hydroxylase domain (PHD) proteins do not hydroxylate these two
prolyl residues, leading to stabilization of HIF-1α. Right panel:I n
normoxia, the hydroxylation of an asparagine residue (Asn 803 for
HIF-1α on the schematic) impairs interaction between the HIFα C-
terminal transactivation domain (C-TAD) and its co-activator p300/
CBP. Under hypoxic conditions, because of the lack of the substrate
oxygen, HIF-asparagine hydroxylase (FIH) does not hydroxylate this
asparagine residue, leading to increased activity of the HIFα C-TAD.
Interestingly the N-TAD is not affected by asparaginyl hydroxylation.
Symbols: , stimulation; , inhibition; , interaction
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which is no longer considered as a pure inhibitor of HIF but
rather as a discriminator between two categories of HIF-
dependent genes: N- and C-TAD targeted genes.
In summary, HIF gene induction is like a ‘four-handed
concerto’ directed by two related but distinct transcription
factors (HIF-1 and -2), each able to independently target
genes with their two transactivation domains (N- and C-
Fig. 3 Model that questions the molecular significance of the two
HIF-1α TAD and the impact of the oxygen sensor FIH on the intra-
tumor location of gene expression as a function of the oxygen
gradient. a Upper panel: If the two HIF-1α TAD are functionally
different they would target different genes. In green are represented
the potential N-TAD-only target genes while in blue are represented
the potential C-TAD sensitive genes. Lower panel: By targeting
specifically the C-TAD, FIH would inhibit only a subset of HIF-
dependent genes. Consequently, FIH would not be a pure inhibitor but
rather a switch between two categories of HIF spectrum genes. b In
accordance with our working model, overexpression of FIH should
delocalize C-TAD sensitive genes (blue dotted line) to highly hypoxic
areas. In contrast FIH inhibition by siRNA should delocalize C-TAD
sensitive genes to moderately hypoxic areas in the vicinity of blood
vessels (lower panel). In parallel, N-TAD only genes (green dotted
line) should not be sensitive to modulation of FIH activity
The hypoxia-inducible factor 57TAD). Yet this model still needs further investigation to
fully appreciate the variation in the repertoire of genes
when induced in a more physiological situation.
The Microenvironment Impacts on HIF and HIF Impacts
on the Microenvironment
So HIF is highly regulated by oxygen via prolyl- and
asparaginyl-hydroxylation, but in turn, a series of HIF
target genes impact on oxygen homeostasis. In the
following section, we will describe how this reciprocity
can be generalized to tumor features including oxygen,
nutrients, pH and the extracellular matrix through a
dialogue between HIF and the microenvironment.
HIF-Directed Modification of Oxygen Homeostasis
A number of HIF-induced genes directly influence envi-
ronmental oxygenation (Fig. 4a). One of the best known is
vascular endothelial growth factor (vegf-a) which favors
the growth of new blood vessels into hypoxic zones [23].
Endothelial tip cells are capable of guiding the growth of
blood capillaries towards hypoxic areas rich in VEGF-A.
These endothelial tip cells emit long filopodia that are very
rich in VEGF-R2 [24]. Hence the chemotactic gradient of
VEGF-A is a guide for neo-vascularization to favor the
sprouting of newly generated vessels toward poorly
oxygenated areas. This phenomenon of angiogenesis,
which is highly HIF-dependent [25], then substantially
remodels the oxygen profile of the ischemic tissue or
hypoxic tumor (Fig. 4b).
Another HIF-dependent molecule that is of great
importance to blood vessel network remodeling is angio-
poietin-2 (Ang-2) [26]. This protein antagonizes Ang-1
binding to its endothelial cell receptor Tie-2 and thereby
prevents blood capillary maturation. The stabilization of the
vascular network is dependent on activation of the Notch
pathway, which results in quiescence of endothelial cells
[27]. In this state, blood vessels are not sensitive to VEGF-
A. So Ang-2, secreted from hypoxic regions of the tumor,
by antagonizing its homologue Ang-1 destabilizes the
organization of capillaries. This destabilization prior to
blood sprouting is an essential step in making endothelial
cells sensitive to VEGF-A and in initiating angiogenesis.
In addition to modulating extracellular oxygen homeo-
stasis, HIF can impact on cellular respiration. It has been
known for a long time that under low oxygen conditions
cells shift from metabolism of glucose through oxygen-
consuming oxidative phosphorylation (OXPHOS) in mito-
chondria to non-oxygen dependent glucose metabolism to
lactic acid in the cytoplasm. This switch has now been
revealed to implicate, at least in part, [28] HIF-induced
Fig. 4 From oxygen to HIF and from HIF to oxygen. a Ad r o pi nt h e
partial pressure of oxygen results in the inactivation of PHDs and FIH.
Consequently the HIF pathway is activated, due respectively to inhibition
of proteasomal degradation and a release of the C-TAD activity. b HIF in
turn impacts on oxygen homeostasis by a double mechanism touching
metabolism (green) and oxygen distribution/angiogenesis (red). HIF
increases the glycolytic flux and represses the entrance of pyruvate into
the Krebs cycle. The consequence is a decrease in oxygen consumption
by mitochondrial respiration. In parallel HIF promotes angiogenesis via
stimulation of vascular endothelial growth factor (VEGF), interleukin-A
(IL-8) and angiopoitin-2 (Ang-2) leading to endothelial cell stimulation
and blood vessel destabilization. In combination, HIF simultaneously
increases tissue perfusion and decreases local oxygen consumption, thus
promoting oxygen diffusion through hypoxic areas
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(Fig. 4b). Thus, HIF has a dual action on oxygen
homeostasis. First, it restores, in the long-term, the oxygen
supply through neo-vascularization and it promotes rapid
reduction of O2 consumption by reducing cell respiration.
Impact of Environmental Nutrients on HIF
Even if oxygen is the main and prototypic driving force of
the HIF pathway, other potential HIF regulators have been
identified. The glucose concentration in tumors follows a
gradient that is very similar to that of the pO2 gradient
described above. The topologies of these gradients are
intimately linked to each other. Glucose, like oxygen, is
delivered by the blood circulation and diffuses into tissues
for cell capture.
The idea that microenvironmental nutrients could influ-
ence HIFα originated from the fact that the enzymatic
reaction catalyzed by oxygen-sensors is dependent on the
metabolite 2-oxoglutarate (2-OG). In vitro studies show that
2-OG is a co-substrate for HIF prolyl and asparaginyl
hydroxylation by respectively, PHD [12] and FIH [11].
Thus, the PHD and FIH activities could be impaired by
reduced levels of 2-OG. Since 2-OG is a product of the
tricarboxylic acid (TCA) cycle (also Krebs cycle) and thus
of glucose metabolism glucose availability could influence
activity. The normal level of 2-OG ranges from 50 et
230 μM[ 29] while the in vitro Km for the PHDs has been
estimated to be about 60 μM[ 30]. This level of affinity
would classify the PHDs as nutritional sensors. Thus,
through 2-OG the PHDs are sensitive to TCA cycle activity
and the balance between aerobic and anaerobic metabolism.
A decrease in the amount of glucose provided to hypoxic
cells was shown to result in a decrease in the level of HIF-
1α [31] or to have no effect [32]. The explanation for this
difference may lie in either the difference in cell lines or the
level of hypoxia (0.1 or 1.0% oxygen) used. Thus, the
sensitivity to glucose in vivo remains to be further clarified.
Another type of nutritional stress, amino-acid depletion,
is able to decrease HIF protein expression by activating the
adenosine monophosphate kinase (AMPK) and mammalian
target of rapamycin (mTOR) pathway (Fig. 5a). In a
situation of an energy imbalance and decrease in intracel-
lular ATP, the tumor suppressor serine/threonine kinase
LKB1 phosphorylates its downstream effector AMPK that
has the potential to target the tuberous sclerosis complex
(TSC1/TSC2) [33]. Once activated, the TSC1/TSC2 com-
plex inhibits mTOR resulting in a decrease in protein
synthesis. Even if it is generally accepted that a decrease in
mTOR activity has a negative effect on HIFα expression,
the mechanisms are controversial. Indeed, HIF protein
synthesis has been shown to be upregulated by mTOR in
various cell types [34, 35]. Genetic evidence reinforces this
link at the level of translation between mTOR and HIF, by
the presence of a 5′-terminal oligopyrimidine tract (5′-TOP)
sequence in the 5′-untranslated region (5′-UTR) of HIF-1α.
5′-TOP sequences can be driven by the S6 ribosomal
protein that is itself a downstream target of mTOR via
p70S6Kinase. Yet it has been demonstrated that mTOR
does not change HIF protein synthesis but modifies
stabilization of HIFα in prostate PC3 cells [36]. This result
is consistent with the fact that the HIF 5′UTR has been
demonstrated to bear an internal ribosome entry site
theoretically allowing HIFα to be translated even in the
absence of mTOR driven CAP dependent translation [37].
Moreover, evidence indicates that HIF protein synthesis can
be controlled by stimulation of an Akt-dependent but
mTOR-independent pathway in PC3 cells [38]. To com-
plete the picture, a feedback loop allows HIF to down-
regulate mTOR via the hypoxia inducible REDD-1 protein
by activating the TSC1/TSC2 signaling integrator complex
[39]. In conclusion, a close link exists between mTOR and
HIF, bringing together two fundamental microenvironmen-
tal constraints: nutrient and oxygen, which are central to
generation of cellular energy.
Impact of HIF on Environmental Nutrients:
from Autophagy to Metabolism
Nutritional deprivation induce a cellular catabolic response
termed autophagy that can rescue cancer cells from cell
death. Autophagy is a phenomenon where proteins,
organelles and cytoplasm of a cell are engulfed into
vacuoles and degraded into constituents for recycling for
maintenance of metabolism and thus cell viability. Thereby,
in tumor cells where apoptosis is defective autophagy
promotes cell survival. However, it is paradoxical that
autophagy is associated with increased tumorigenesis by a
mechanism that remains to be defined. It has been
suggested that autophagy protects cells from tumor necrosis
and inflammation, and diminishes DNA damage in the
tumor cell response to metabolic stress [40].
While HIF is a major actor in the cell survival response
to hypoxia, HIF has also been associated with cell death.
Indeed several studies have pointed to the implication of the
HIF-induced putative BH3 only pro-apoptotic genes Bcl2/
adenovirus E1B19kD protein interacting protein 3 (bnip3)
and bnip3 like (bnip3L) in hypoxia-mediated cell death [41,
42]. We and others failed to reproduce the pro-apoptotic or
necrotic cell death features of ectopically expressed BNIP3
or BNIP3L in various cell types including MEFs, MCF7,
PC3 or LS174 cells. Therefore, we seriously questioned the
cell death function of BNIP3/BNIP3L in a hypoxic
environment and rather postulated on a positive role in
activating the autophagic cell survival process [43]. Using a
large panel of normal cells and tumor cell lines, we
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(1% O2) were required to initiate autophagy. Whereas
siRNA-mediated ablation of either BNIP3 or BNIP3L had
little effect, combined silencing of the two HIF targets
suppressed hypoxia-mediated autophagy. BNIP3 and
BNIP3L are therefore major players of the HIF-mediated
survival response in tumors and ischemic tissues. We
propose a model in which the hypoxia-induced BNIP3/
BNIP3L proteins are essential to disrupt the Bcl2/Beclin1
complex ([44], Mazure et al. in preparation). It is interesting
to note that autophagy is triggered in conditions of full
availability of nutrients (glucose, amino acids) and growth
factors; the only limiting factor is oxygen. We propose that
the pO2 is, as for angiogenesis, the primary signal capable
of preparing the tumor cell to endure prolonged nutrient
starvation by inducing autophagy.
From a metabolic view point, the cellular energetic
balance of hypoxic tumor cells is compromised by the shift
away from OXPHOS, as mentioned above, since the
alternative i.e. conversion of glucose to lactate produces
less energy. To make up for lower ATP production tumor
cells increase the capture of glucose and the flux of
glycolysis through HIF-mediated induction of genes of
glucose transporters such as glut-1and glut-3, and glyco-
lytic enzymes like pgk1 (Fig. 5b). In addition, HIF redirects
the fate of pyruvate as a result of two concordant actions:
(1) by upregulating the gene lactate dehydrogenase-a (ldh-a),
the protein product of which favors the conversion of
pyruvate to lactate [45] (2) by repressing OXPHOS through
induction of the expression of pyruvate dehydrogenase
kinase-1 (PDK-1), an inhibitor of pyruvate dehydrogenase
(PDH), the enzyme that drives pyruvate into the TCA cycle
for mitochondrial respiration [46, 47]. Finally HIF impacts
on OXPHOS by modulating cytochrome c oxidase (COX)
isoform expression [48]. In fact, oxygen is the final acceptor
in the mitochondrial electron transport chain and COX, or
more precisely COX-4 of complex IV, catalyzes the reaction
with production of H2O[ 49]. When this reaction is not
sufficiently active oxygen is the final electron at the level of
complex I or III that produces reactive oxygen species
(ROS). The expression of COX4-1 and COX4-2, two
isoforms of complex IV, is differentially regulated by HIF
glucose
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Fig. 5 From nutrients to HIF and from HIF to metabolism. a Two
different pathways involved in the response to nutrients impact on
HIF. First a decrease in the amount of glucose can inhibit the activity
of FIH and PHD through decreased production of the co-substrate 2-
oxoglutarate by the Krebs cycle. However, it is not sure that it is
limiting in vivo. The question as to whether FIH and PHD might be
nutritional sensors is still open to discussion. The second pathway
responds to nutrient depletion reflecting a decrease in the ATP/AMP
ratio. This nutritional stress activates the LKB1/AMPK/TSC1/TSC2
pathway resulting in an inhibition of mammalian target of rapamycin
(mTOR). The action of mTOR on HIF is still a subject of debate.
Essentially two options have been proposed: inhibition of HIF
translation and/or inhibition of proteasomal degradation. Both con-
verge in the activation of HIF under nutrient depletion conditions. b
HIF can in turn impact on metabolism and cellular energy due to
induction of a variety of target genes (here in green). It promotes
glucose import via glucose transporters (GLUT1, 3) and it increases
the rate of glucose consumption by inducing expression of glycolytic
enzymes. HIF also promotes a shift to anaerobic metabolism by:
favoring conversion of pyruvate to lactate through enhanced expres-
sion of the enzyme LDH-A and by increased expression of PDK-1
that counteracts the entrance of pyruvate into the Krebs cycle. Finally,
through REDD-1, HIF stimulates the TSC1/2 complex, creating a
negative feedback loop on mTOR. In summary, HIF allows cancer
cells to shift to highly glycolytic anaerobic metabolism and to save
energy by downregulating translation in a mTOR-dependent fashion
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since LON in turn degrades COX4-1 [48]. Thus, in hypoxia
COX4-2 substitutes for COX4-1, an isoform that is
suggested to be more efficient in oxygen utilization. In this
way cells exploit more efficiently low oxygen levels and
avoid production of harmful ROS under hypoxic conditions.
Impact of Environmental pH on HIF
Another important feature of the tumor microenvironment
is acidosis, which is a consequence of the boost in
glycolysis leading to production of lactic acid and of
defective vascular evacuation of metabolic lactic acid and
CO2 [50]. As for oxygen and nutrients, a gradient of
acidosis is established from blood vessels to the periphery
of a tumor. The decrease in oxygen and pH was examined
along a length of 300 μm from blood vessels in a breast
cancer xenograft mouse model and a drop in pO2 from 12
to 0 mmHg and in extracellular pH (pHe) from 7.4 to 6.7
was reported [51]. The question as to whether pH can
influence the HIF pathway was first examined through an
indirect effect on the VHL protein, a component of the
HIFα ubiquitin ligase complex [52] (Fig. 6a). Acidosis was
shown to induce relocalization of the VHL protein into
nucleoli. However, it is still not clear if a drop in pH on its
own, is sufficient to allow HIF to bypass polyubiquitylation
and thus escape proteasomal degradation. Results from our
laboratory show that a low pH is not necessarily associated
with HIFα stabilization (unpublished results), which was
corroborated in a recent publication [53].
Low pH has also been shown to modulate two HIF-
induced genes: vegf and bnip3. Both pH and hypoxia can
independently induce vegf in human glioma cells [54] and
the extracellular-regulated kinase (ERK) pathway is an
independent intermediary candidate up-regulating the level
of vegf in a pH-sensitive manner [55]. Although low pH
does not increase BNIP3 protein expression it increases its
activity in regulating cell death in cardiomyocytes [56]. It is
possible to hypothesize that HIF-1 induces BNIP3 in
moderate hypoxic regions whereas the pH gradient pilots
BNIP3-directed cell death only in highly acidic/hypoxic
areas [43]. Thus, low pH might be a major contributor in
sensitizing cells to necrotic cell death. Nevertheless the link
between HIF and cell death is a highly debated subject and
the precise conditions of hypoxia-induced cell death in
tumors still needs to be clarified [57].
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Fig. 6 From pH to HIF and from HIF to pH. a It has been proposed
that acidosis could protect HIFα from proteasomal degradation by
sequestering the component of the VHL E3 ubiquitin ligase complex
in nucleoli. b HIF acts both directly and indirectly on the pH. On the
one hand, by stimulating glycolysis (green) it favors the production of
lactate and protons that could potentially acidify the intracellular
medium. On the other hand HIF promotes intracellular alkalinization
(yellow) by activating monocarboxylate transporter (MCT1, 4) and
Na
+/H
+ exchanger (NHE1, 6) that are able to evacuate lactate and
protons, respectively. Simultaneously, the membrane carbonic anhy-
drases (CA) CA IX and CA XII isoforms acidify the extracellular
matrix by converting CO2 and H2O into HCO3
- and H
+. Our group
hypothesizes that while protons acidify the extracellular medium,
bicarbonate could be recaptured in order to alkalinize the cell. In
summary HIF compensates for the intracellular production of lactic
acid associated with anaerobic metabolism by a process of intracel-
lular alkalinization that is linked to extracellular acidification
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Thus, hypoxia and acidosis cohabit in tumors but both
undermine cell survival. In response, HIF triggers an
adaptation strategy that leads to induction of specific genes
dedicated to pH homeostasis (Fig. 6b). The gene products
include the Na
+/H
+ exchanger (NHE) that extrudes protons
from the cytoplasm at the expense of the Na
+ gradient and
the monocarboxylate transporter (MCT) that evacuates
lactic acid. The expression of the MCT4 [58], NHE1 [59]
and NHE6 [47] isoforms is induced in hypoxia and the
exchange activity of NHE1 is increased [58, 60]. MCT can
transport lactate in both the intracellular and extracellular
direction. Thus, lactate may be considered as both an acidic
waste product and a source of energy, as has been shown
for muscles and hypothesized for neurons [61]. In a tumor
it may be envisaged that a cancer cell excretes lactate to be
taken-up by neighboring fibroblasts for subsequent use by
the TCA cycle. In fact, it has been shown that fibroblasts in
contrast to cancer cells express a high level of PDH and a
low level of PDK1 [62]. Thereby fibroblasts through an
oxidative utilization of lactate may promote extracellular
lactate clearance. The intracellular transport of lactate by
endothelial cells that express active MCT1 [63] in tumors
may also modify the microenvironment through promoting
angiogenesis [64].
In addition, the membrane bound carbonic anhydrases
(CA) CA IX, one of the most HIF-sensitive genes, and CA
XII convert environmental CO2 into bicarbonate which may
alkalinize the intracellular pH (pHi), possibly through
capture by Na
+-dependent and -independent Cl
-/HCO
3−
exchangers [65].
Impact of the Extracellular Matrix on HIF
The extracellular matrix (ECM) indirectly impacts on all
these environmental characteristics. Oxygen and nutrient
diffusion are dependent on the stroma density, vasculature
and cellular three-dimensional organization. Beside these
physical characteristics, the chemical composition of the
stroma can also be a determining feature (Fig. 7a). For
instance, growth factors can modulate the HIFα protein
level. Insulin like growth factor 1, epithelial growth factor
and epithelial growth factor 2 (HER2/Neu) have been
shown to induce HIF-1α expression in respectively, colon
carcinoma cells (HCT116) [66], prostate cancer cells
(DU145, PC-3, PPC-1, and TSU) [67] and breast cancer
cells (MCF-7) [35]. These three factors increase the HIFα
protein level via the phosphatidylinositol-3-kinase (PI3K)/
Akt pathway targeting mTOR. However, the ERK pathway
is also a candidate for HIF modulation by growth factors
since HIF activity is stimulated through ERK-dependent
signaling [68]. At least two mechanisms might explain
HIFα up-regulation by ERK: the co-activator p300 that
enhances HIF activity by binding to the C-TAD of HIF may
be targeted by phosphorylation leading to a more favorable
p300-HIF-TAD interaction [69], and/or HIF targeted phos-
phorylation may promote HIF-1α nuclear localization [70].
In addition, vasoactive hormones such as angiotensin II that
are secreted by stromal cells can promote both HIF
translation in a PI3K-dependent manner and HIF transcrip-
tion through the action of the diacylglycerol-sensitive
protein kinase C in vascular smooth muscle cells [71].
HIF-Directed Modification of the Extracellular Matrix
A series of hypoxia induced phenomena impact on the
ECM. Indirectly, hypoxia-related acidosis can modulate the
composition and architecture of the ECM, which in turn
impacts on three-dimensional cellular organization and
promotes metastasis (Fig. 7b). In a more direct fashion,
hypoxia, through HIF is a modulator of lysyl oxidase
(LOX) [9, 72], an enzyme that catalyzes collagen and
elastin crosslinking [73]. Furthermore, stimulation of LOX
by HIF is an essential intermediary of hypoxia-promoted
metastasis [72, 74]. Surprisingly the canonical action of
LOX on collagen and elastin might not be the key to this
pathway but rather peroxide production, a side product of
LOX activity, and focal adhesion kinase activity may be at
the center of this pathway. However, the question as to
whether LOX is associated positively or negatively with
tumor development has hardly been discussed [72, 74–76],
yet this ECM modifier is strongly induced by hypoxia.
The significance of LOX in cancer should be reconsidered
taking into account the hypoxic status of a given tumor.
Another family of proteins that modifies the ECM and that
is directly involved in metastasis is the matrixmetalloproteases
(MMP). These proteins participate in the destruction of the
ECM, an action known to be essential for cellular migration.
MMP-2 and membrane type 1-MMP1 expression [77, 78]h a s
been shown to be responsive to HIF-1 and HIF-2, respec-
tively. In the same context, metabolic changes and HIF action
have been shown to play a role in adhesion, in particular in
interaction with vascular endothelial cells through a selectin-
and integrin-mediated pathway [79]. Evidence for HIF
negative regulation of E-cadherin might also provide another
clue to elucidate how cancer cells lose contact and proceed to
epithelial to mesenchymal transition leading to metastasis
[80–82]. This process is particularly relevant in renal cell
carcinoma where the loss of the ubiquitin ligase VHL protein
function correlates with overexpression of HIF. Nonetheless
the intermediary signal linking HIF and E-cadherin remains
to be identified. Another group of HIF-dependent genes
impacting on the remodeling of the ECM include, fibronectin,
cathepsin D and urokinase plasminogen activator [5]. Yet
another series of genes products also induced by HIF has
62 F. Dayan et al.been shown to promote cell invasion: the autocrine motility
factor [83], vimentin, the receptor tyrosine kinase c-Met [84],
the stromal derived factor-1, keratins 14, 18 and 19 and the
cytokine receptor CXCR4 [85, 86].
Finally, the inflammatory status of the tumor stroma is a
crucialelementofthemicroenvironmentandtheHIFpathway
can modulate the cellular inflammatory response. On the one
hand, by promoting glycolysis, lactate production and thus
extracellular acidification, HIF indirectly inhibits a subset of
inflammatory actors: human cytotoxic T lymphocytes [87]
(which are sensitive to lactate) and natural killers [88]
(inactivated at low pH). On the other hand, HIF is a
powerful driving force behind the action of tumor associated
macrophages (TAM). As a result of over activation of the
HIF pathway that increases glycolysis TAM are supplied
with the energy necessary to migrate to tumor sites [89].
Consequently, TAM have a propensity to move toward areas
distant from the circulation such as hypoxic and peri-necrotic
zones [90]. In addition, they contribute to tumor aggressive-
ness through their ability to promote angiogenesis, extracel-
lular matrix remodeling and cancer cell migration [91, 92].
This large body of data reveals the global role of HIF in
tumor cell adaptation to microenvironmental stress. Com-
mencingwithadecreaseinthepO2 as the main regulator, this
transcription factor initiates a cascade of events that modifies
profoundly the microenvironment: tissue perfusion, metabo-
lism, acidosis, matrix remodeling, proteolysis, and cellular
migration. Taken together these data place HIF at the center
of potential anti-environmental directed therapies.
Anti-cancer Therapy: A Few Hints on How to Disrupt
Hypoxic Microenvironmental Adaptation
Clinical findings indicate that both hypoxia [5] and the
characteristics of the tumor microenvironment [93] are
related to the aggressiveness of a cancer.
Fig. 7 From the extracellular matrix to HIF and from HIF to the
extracellular matrix. a The extracellular matrix (ECM) is an essential
component of the physicochemical environment of the cell, and
includes fibrous proteins, glycoconjugates, growth factors and
hormones. The chemical composition of the ECM can impact on
HIF through growth factor stimulation. It has been shown that growth
factors, by activating phosphatidylinositol-3-kinase (PI3K), can target
mTOR and consequently HIF. As discussed above, the action of
mTOR on HIF is a subject of debate. Essentially two options have
been proposed: inhibition of HIF translation and/or inhibition of
proteasomal degradation. Both converge to activate HIF. Growth
factors could also activate HIF through the extracellular-regulated
kinase (ERK) pathway. It has been proposed that phosphorylation of
HIF by ERK could indirectly increase HIF activity by inhibiting the
export of this transcription factor from the nucleus. As a consequence
the activation of HIF target genes would be more efficient when HIF
is phosphorylated. Moreover the vasoactive hormone angiotensin II
has been shown to promote HIF-1α transcription through a protein
kinase B (PKB) dependent mechanism. Finally, the physical density of
the ECM could also indirectly influence the HIF pathway by
modulating the oxygen diffusion length (not shown here). b A variety
of HIF-induced genes have been shown to directly play a role on cell
motility, invasion and extracellular matrix modulation (blue). A
hypothetical mechanism for the loss of cell junctions under hypoxia
could implicate the HIF-dependent activation of lysyl oxidase-like 2
(LOXL2) leading to stimulation of Snail. This transcriptional inhibitor
could then downregulate E-cadherin (E-cad) and promote invasion.
However, the subject of the ECM is also linked to other HIF-
dependent actions, for instance, extracellular acidification could
participate in mechanisms of invasion. Finally, the growth of neo-
vessels, under the control of HIF, is also a crucial element in the
penetration of cancer cells into the circulation. Autocrine motility
factor (AMF); chemokine receptor CXCR4; receptor tyrosine kinase c-
Met; lysyl oxidase (LOX); matrix metalloproteases (MMP)
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cellular stress situation giving rise to an unfavorable
energetic balance, which should lead to diminished cell
proliferation. Nonetheless, clinical studies have shown that
the global hypoxic status of tumors is not correlated with a
low rate of cancer cell proliferation. On the contrary, the
degree of hypoxia in tumors positively correlates with bad
prognosis [1]. These data indicate that severe hypoxia and a
hostile microenvironment exert on tumor cells a drastic
selection pressure leading to the emergence of tumor clones
able to survive and migrate out of the nutrient-deprived
environment. Therefore, from a therapeutic point of view, it
is important to identify and antagonize the most pertinent
adaptation mechanisms that allow tumor cells to escape this
hostile milieu. Although this is a big challenge, basic
knowledge of hypoxia signaling should allow development
of rationalized novel anti-cancer strategies.
An Oxygen Centered Anti-microenvironmental Strategy
Based on the fact that O2 is the main regulator of the HIF
pathway, and that clinically hypoxic tumors are associated
with poor patient survival, interfering with oxygen homeo-
stasis constitutes an interesting anti-cancer approach.
However, hypoxia is both a cytotoxic stress and a stimulus
in initiating adaptation. The balance between the good and
the bad side of hypoxia is very fine and might be tumor
type dependent.
An illustration of the difficulty in foreseeing and
controlling the precise effects of oxygen can be found in
the controversy touching hyperbaric oxygen therapy
(HBO). This type of treatment consists in submitting
patients to 100% oxygen at a pressure higher than one
atmosphere. The idea is to decrease the hypoxic score of the
tumor. Contradictory results have emerged both from
clinical investigation and animal experimentation [94].
HBO therapy can be pro- or anti-proliferative, or even
inactive. On the one hand, oxygenation decreases the HIF
microenvironmental adaptation response, but on the other
hand it brings precious fuel to cancer cells.
The goal of anti-angiogenic approaches is to disturb
vessels and consequently the oxygen profile in the tumor.
By inhibiting VEGF [23, 95] or the endothelial VEGF-
receptor [96–98] the formation of new vessels, a crucial
process in the dynamics of tumor growth, is impaired.
However, this approach paradoxically has limitations since
anti-angiogenic agents will increase the hypoxic score of
tumors, which is likely to increase cell virulence (Fig 8).
Another strategy consists in considering oxygen as a
landmark of the HIF adaptive pathway where oxygen is a
kind of environmental messenger dictating HIF function.
An interesting strategy would be to specifically target
hypoxic cells. In fact, their location, distant from blood
vessels contributes physically to their resistance to classical
chemotherapy (delivered by the circulation) and radiother-
apy (that uses oxygen as an intermediary target to generate
Fig. 8 Cyclic dynamics of tumor growth and putative anti-cancer
approaches. Massive tumor cell proliferation leads to the formation of
hypoxic zones at the periphery of blood vessels. The hypoxic signal
stimulates a series of adaptation genes controlled by both the N-TAD
and C-TAD of HIF-1α. Consequently, a set of adaptative changes (for
instance involved in angiogenesis) make the microenvironment
permissive for cell proliferation (for instance by reoxygenating
hypoxic areas). From a therapeutic point of view, there are different
ways to break this cycle. Classical chemotherapy inhibits cell
proliferation but results in severe patient side-effects. Anti-angiogenics
aim at blocking one feature of this adaptation phenomenon: the
growth of new blood vessels. An alternative strategy consists in
abolishing the overall adaptation mechanism by disorganizing the
HIF-target genes. In addition, FIH inhibitors would represent a new
class of anti-cancer drugs. Such candidate molecular targets may lead
to innovative anti-microenvironmental adaptation approaches
64 F. Dayan et al.toxic free radicals). Hypoxic cells are thus particularly
strategic targets. Compounds such as tirapazamine (TPZ)
[99–101] are pro-drugs that become activated by the
reducing effect of a drop in oxygen tension. Therefore their
toxicity is targeted to hypoxic areas in tumors. However, the
question of diffusion of this kind of drug from blood vessels
still needs to be addressed. Yet it is conceivable that their
lower non-specific toxicity should allow high dosage. Future
studies should evaluate the exact sensitivity and toxicity of
this kind of treatment. Interestingly the activity of the HIF
pathway has been shown to decrease TPZ activity probably
due to the redistribution of intracellular oxygen following
mitochondrial inhibition [47]. This recent data suggests that
a combined anti-HIF and TPZ therapy should clearly
improve treatment. Alternatively, the hypoxic characteristic
of tumors can be exploited in therapy by using obligate
anaerobic bacteria such as clostridia, which show lytic
activity in tumor cells [102].
The hypoxic status of a tumor might also be considered
as a key parameter in the choice of the anti-cancer arsenal
of physicians. Susceptibility of a given drug could indeed
be oxygen dependent [103]. For instance this seems to be
the case for the proteasome inhibitor bortezomib [104] and
for mTOR inhibitors [105]. Thus the hypoxic score might
not only be predictive of the tumor aggressiveness but also
guide the clinician in the therapeutic strategy to adopt.
A Non-oxygen Centered Anti-microenvironmental Strategy
Clinical evidence suggests that HIF-1 overexpression is
associated with higher cancer mortality or treatment
resistance and thus inhibition of HIF activity has been
proposed [5]. A number of HIF modulators that target
different steps in HIF function are currently under evalu-
ation [5, 103, 106]. However, the benefit of such a
therapeutic approach remains speculative since HIF is a
pleiotropic factor, able to promote survival, proliferation,
and cell death, thus modulating its action might have drastic
consequences on general physiology. Thus, instead of
targeting HIF itself, targeting a particular set of HIF
downstream products may show potential. However, this
strategy might suffer from the complexity and potential
redundancy of the HIF pathway. Even if a precise
adaptation gene is inactivated, the relay may be taken up
by one of the myriad of HIF downstream targets. The
expected cytotoxic effect could possibly be circumvented
thanks to another microenvironmental adaptation phenom-
enon. Interrupting the dialogue between HIF and the
microenvironment certainly appears to be complex and
requires an in-depth understanding of the mechanisms
involved in regulation.
Agents such as echinomycin impair HIF-1 association
with its target DNA [107] while growth factor directed
therapies such as traztuzumab (Herceptin), which inhibits
HER2/Neu, indirectly decrease HIF-1α protein levels [35,
106]. Benzoquinone ansamycin drugs like geldanamycin,
also decrease the HIF-1α protein level by favoring its
proteasomal degradation [108]. Alternately, interest in
developing HIF activating drugs in the treatment of
ischemic disorders has led to research into agents such as
dimethyloxaloylglycine which inhibit the 2-OG dependent
dioxygenase activity resulting in stabilization and activation
of HIFα [109].
As mentioned, selective inhibition of the appropriate
HIF-downstream gene product may be preferable. VEGF
and VEGF-R are such targets and although precursors in
this approach they may not be the only HIF downstream
targets of interest. The combination of the anti-angiogenic
with anti-HIF metabolic adaptation agents could be envis-
aged by interfering with key glycolytic enzymes such as
LDH-A. Another strategy would consist in impairing the
HIF-induced pHi regulating system [43]. In this case, the
natural propensity of cancer cells to switch to pyruvate
metabolism to lactic acid and consequently to acidosis
would impact on proliferation. As a proof of principle,
genetically altered cell lines that are not able to regulate
their pHi do not proliferate normally under acidic con-
ditions and show a very poor tumorigenic potential in
xenograft experiments [110]. From a therapeutic point of
view, the expected cytotoxicity would result from necrotic
cell death sensitized by intracellular acidosis.
A third approach, which is a compromise between the
previous ones, would be to exploit the HIF pathway by
destabilizing its global pro- and anti-survival balance in
favor of tumor regression. This would consist in targeting a
qualitative modulator of the HIF activity. In this context,
FIH would be an interesting candidate. Indeed, we
discussed above the potential role of FIH as a discriminator
between two subtypes of genes and as a determinant of the
gene localization in a tumor hypoxic gradient [20]. The FIH
activity would direct the expression of a precise gene at a
precise localization in the tumor, associated with a given
oxygen tension. It is likely that genes associated with cell
death and anti-proliferation are activated in severe hypoxic
regions whereas survival genes are induced in milder
hypoxic zones. Displacing anti-survival genes to oxygenat-
ed regions might be of great interest. By targeting FIH, our
working model predicts such a disorganization of the whole
gene pattern that we believe should impair the general
microenvironmental adaptation process.
Conclusions
The microenvironment dictates its constraints on HIF
mainly via the oxygen level, and in turn HIF responds by
The hypoxia-inducible factor 65pleiotropic and sometimes apparently contradictory effects.
The prospect of altering this signaling network in develop-
ing tumor specific anti-environmental adaptation therapies
holds promise. However, efficacious strategies that target
microenvironmental adaptation will only emerge from a full
understanding of the whole adaptation process. Success will
depend on: (1) the identification of the most pertinent HIF
downstream gene product to be targeted and (2) the
elucidation of the global orchestration of adaptation genes.
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